Eckert & Ziegler SE (ETR:EUZ)

Market Cap	1.03B -22.9%
Revenue (ttm)	316.71M +6.8%
Net Income	49.44M +43.4%
EPS	0.79 +43.2%
Shares Out	62.57M
PE Ratio	20.92
Forward PE	19.50
Dividend	0.22 (1.36%)
Ex-Dividend Date	Jun 25, 2026

Volume	173,739
Open	16.42
Previous Close	16.20
Day's Range	16.40 - 16.84
52-Week Range	13.30 - 23.25
Beta	1.48
Analysts	Strong Buy
Price Target	22.10 (+33.78%)
Earnings Date	May 12, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Employees: 1,116
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EUZ

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.